echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > DRCP: A comparative study of a combination of glimepiride/metformin fixation and monotherapy in patients with type 2 diabetes

    DRCP: A comparative study of a combination of glimepiride/metformin fixation and monotherapy in patients with type 2 diabetes

    • Last Update: 2022-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Background: Type 2 diabetes mellitus (T2DM) is one of the most common metabolic disorders, and glycemic control usually begins with oral hypoglycemic drugs


    Objective: The objective of this study was to analyze the efficacy, insulin sensitivity and safety


    Methods: A randomized, open-ended, parallel, 16-week trial was conducted in four research centers


    Results: Compared with the G group, HbA1c and PPG 2 h in the G/M group were significantly reduced


    Table 1 - Insulin glargine dose control algorithm


    Table 2 Equivalence and power analysis of endpoint parameter changes

    Table 3 Endpoint Response Rate (ITT


    Conclusions: A comparison of combination therapies consisting of either the G/M group or the G group showed that both forms of treatment were relatively safe, but the former was more effective at lowering blood glucose levels


    Original source :Yu HM, Kim SJ, Chun SW, et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.